• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis.

作者信息

Singh Awadhesh Kumar, Singh Ritu

机构信息

Department of Endocrinology, GD Hospital and Diabetes Institute, Kolkata, West Bengal, India.

Department of Gynecology, GD Hospital and Diabetes Institute, Kolkata, West Bengal, India.

出版信息

Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):4-10. doi: 10.4103/2230-8210.196026.

DOI:10.4103/2230-8210.196026
PMID:28217490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5240079/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/59e0f231bbfc/IJEM-21-4-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/92d3e4c44eb1/IJEM-21-4-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/3bef225744ac/IJEM-21-4-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/6d82d275b354/IJEM-21-4-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/1cbd9b81fafe/IJEM-21-4-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/9ff49c9884fa/IJEM-21-4-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/f2c7fa279be5/IJEM-21-4-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/59e0f231bbfc/IJEM-21-4-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/92d3e4c44eb1/IJEM-21-4-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/3bef225744ac/IJEM-21-4-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/6d82d275b354/IJEM-21-4-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/1cbd9b81fafe/IJEM-21-4-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/9ff49c9884fa/IJEM-21-4-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/f2c7fa279be5/IJEM-21-4-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/620d/5240079/59e0f231bbfc/IJEM-21-4-g010.jpg

相似文献

1
Recent cardiovascular outcome trials of antidiabetic drugs: A comparative analysis.近期抗糖尿病药物的心血管结局试验：一项比较分析。
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):4-10. doi: 10.4103/2230-8210.196026.
2
Glycosylated Hemoglobin as a Surrogate for the Prevention of Cardiovascular Events in Cardiovascular Outcome Trials Comparing New Antidiabetic Drugs to Placebo.糖化血红蛋白作为比较新型降糖药物与安慰剂心血管结局试验中预防心血管事件的替代指标。
Cardiology. 2020;145(6):370-374. doi: 10.1159/000506004. Epub 2020 Feb 21.
3
Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis.新型抗糖尿病药物类别临床试验中的心血管结局：网络荟萃分析。
Cardiovasc Diabetol. 2019 Aug 28;18(1):112. doi: 10.1186/s12933-019-0916-z.
4
Cardiovascular risk of oral antidiabetic drugs: current evidence and regulatory requirements for new drugs.口服抗糖尿病药物的心血管风险：新药的现有证据和监管要求
J Assoc Physicians India. 2012 Jan;60:56-61.
5
Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.口服抗糖尿病药物预防心血管疾病死亡率和发病率的比较效果：一项网状Meta分析。
PLoS One. 2017 May 25;12(5):e0177646. doi: 10.1371/journal.pone.0177646. eCollection 2017.
6
Efficacy and Cardiovascular Safety of Antidiabetic Medications.抗糖尿病药物的疗效和心血管安全性。
Curr Drug Saf. 2021;16(2):115-121. doi: 10.2174/1574886316666210112153429.
7
Antidiabetic drugs and blood pressure changes.抗糖尿病药物与血压变化。
Pharmacol Res. 2020 Nov;161:105108. doi: 10.1016/j.phrs.2020.105108. Epub 2020 Jul 30.
8
Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.2型糖尿病患者中与二肽基肽酶-4抑制剂及其他抗糖尿病药物相关的心血管疾病风险：一项全国性纵向研究
Cardiovasc Diabetol. 2016 Mar 1;15:41. doi: 10.1186/s12933-016-0350-4.
9
Understanding the cardiovascular risk with non-insulin antidiabetic drugs.了解非胰岛素类抗糖尿病药物的心血管风险。
Expert Opin Drug Saf. 2019 Mar;18(3):241-251. doi: 10.1080/14740338.2019.1586881. Epub 2019 Mar 8.
10
Effects of first-line antidiabetic drugs on the improvement of arterial stiffness: A Bayesian network meta-analysis.一线抗糖尿病药物对改善动脉僵硬度的影响：一项贝叶斯网络荟萃分析。
J Diabetes. 2023 Aug;15(8):685-698. doi: 10.1111/1753-0407.13405. Epub 2023 May 10.

引用本文的文献

1
Cost-benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand.利拉鲁肽与西他列汀治疗泰国2型糖尿病的成本效益比较
Clinicoecon Outcomes Res. 2019 Jul 11;11:423-430. doi: 10.2147/CEOR.S201951. eCollection 2019.
2
Importance of Postprandial Glucose in Relation to A1C and Cardiovascular Disease.餐后血糖与糖化血红蛋白及心血管疾病的关系
Clin Diabetes. 2019 Jul;37(3):250-259. doi: 10.2337/cd18-0040.
3
SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins.

本文引用的文献

1
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
2
Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.利拉鲁肽对射血分数降低的晚期心力衰竭患者临床稳定性的影响：一项随机临床试验。
JAMA. 2016 Aug 2;316(5):500-8. doi: 10.1001/jama.2016.10260.
3
Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
SAVOR-TIMI研究至DECLARE-TIMI研究：关于肠促胰岛素调节剂和格列净类药物心血管结局试验的综述
Indian J Endocrinol Metab. 2019 Mar-Apr;23(2):175-183. doi: 10.4103/ijem.IJEM_12_19.
4
A Review on Cardiovascular Outcome Studies of Dipeptidyl Peptidase-4 Inhibitors.二肽基肽酶-4抑制剂心血管结局研究综述
Indian J Endocrinol Metab. 2018 Sep-Oct;22(5):689-695. doi: 10.4103/ijem.IJEM_104_18.
西格列汀使用与 2 型糖尿病心力衰竭住院及相关结局的关系：一项随机临床试验的二次分析。
JAMA Cardiol. 2016 May 1;1(2):126-35. doi: 10.1001/jamacardio.2016.0103.
4
The Safety of Dipeptidyl Peptidase 4 Inhibitors and the Risk for Heart Failure.二肽基肽酶4抑制剂的安全性与心力衰竭风险
JAMA Cardiol. 2016 May 1;1(2):123-5. doi: 10.1001/jamacardio.2016.0184.
5
Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?恩格列净对2型糖尿病患者的死亡率益处是否好得令人难以置信？
Circulation. 2016 Jul 12;134(2):94-6. doi: 10.1161/CIRCULATIONAHA.116.022537.
6
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.利拉鲁肽与2型糖尿病患者的心血管结局
N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.
7
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.利西拉肽治疗 2 型糖尿病合并急性冠状动脉综合征患者的疗效。
N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.
8
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
9
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.西格列汀对 2 型糖尿病患者心血管结局的影响。
N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8.
10
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).利格列汀与格列美脲在2型糖尿病中的心血管结局试验（CAROLINA®）的设计与基线特征
Diab Vasc Dis Res. 2015 May;12(3):164-74. doi: 10.1177/1479164115570301. Epub 2015 Mar 15.